Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

MDM2 promotes cell motility and invasiveness through a RING-finger independent mechanism.

Polański R, Warburton HE, Ray-Sinha A, Devling T, Pakula H, Rubbi CP, Vlatković N, Boyd MT.

FEBS Lett. 2010 Nov 19;584(22):4695-702. doi: 10.1016/j.febslet.2010.10.049. Epub 2010 Oct 29.

2.

Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.

Noon AP, Polański R, El-Fert AY, Kalirai H, Shawki H, Campbell F, Dodson A, Eccles RM, Lloyd BH, Sibson DR, Coupland SE, Lake SL, Parsons K, Vlatković N, Boyd MT.

BJU Int. 2012 Apr;109(8):1250-7. doi: 10.1111/j.1464-410X.2011.10433.x. Epub 2011 Jul 14.

3.

MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility.

Polanski R, Maguire M, Nield PC, Jenkins RE, Park BK, Krawczynska K, Devling T, Ray-Sinha A, Rubbi CP, Vlatkovic N, Boyd MT.

Carcinogenesis. 2011 Aug;32(8):1133-42. doi: 10.1093/carcin/bgr070. Epub 2011 Apr 18.

PMID:
21504894
4.

Mdm2-mediated ubiquitylation: p53 and beyond.

Marine JC, Lozano G.

Cell Death Differ. 2010 Jan;17(1):93-102. doi: 10.1038/cdd.2009.68. Review.

5.

p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

Noon AP, Vlatković N, Polański R, Maguire M, Shawki H, Parsons K, Boyd MT.

Cancer. 2010 Feb 15;116(4):780-90. doi: 10.1002/cncr.24841. Review.

6.

MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.

Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R.

Clin Cancer Res. 2007 Jul 15;13(14):4123-9.

7.

Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.

Wang L, He G, Zhang P, Wang X, Jiang M, Yu L.

Mol Biol Rep. 2011 Jan;38(1):229-36. doi: 10.1007/s11033-010-0099-x. Epub 2010 Mar 24.

PMID:
20333547
8.

p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug.

Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH, Yuan A, Lin CW, Yang SC, Chan WK, Li KC, Hong TM, Yang PC.

Nat Cell Biol. 2009 Jun;11(6):694-704. doi: 10.1038/ncb1875. Epub 2009 May 17. Erratum in: Nat Cell Biol. 2009 Jul;11(7):914.

PMID:
19448627
9.

Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice.

Jung CR, Lim JH, Choi Y, Kim DG, Kang KJ, Noh SM, Im DS.

J Clin Invest. 2010 Dec;120(12):4493-506. doi: 10.1172/JCI42674. Epub 2010 Nov 8.

10.

Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2.

Nie J, Xie P, Liu L, Xing G, Chang Z, Yin Y, Tian C, He F, Zhang L.

J Biol Chem. 2010 Jul 23;285(30):22818-30. doi: 10.1074/jbc.M110.126920. Epub 2010 May 18.

11.

P53 mRNA controls p53 activity by managing Mdm2 functions.

Candeias MM, Malbert-Colas L, Powell DJ, Daskalogianni C, Maslon MM, Naski N, Bourougaa K, Calvo F, Fåhraeus R.

Nat Cell Biol. 2008 Sep;10(9):1098-105. doi: 10.1038/ncb1770.

PMID:
19160491
12.

The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor.

Manfredi JJ.

Genes Dev. 2010 Aug 1;24(15):1580-9. doi: 10.1101/gad.1941710. Review. Erratum in: Genes Dev. 2010 Sep 15;24(18):2105.

13.

Mdm2 facilitates the association of p53 with the proteasome.

Kulikov R, Letienne J, Kaur M, Grossman SR, Arts J, Blattner C.

Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10038-43. doi: 10.1073/pnas.0911716107. Epub 2010 May 17.

14.

Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans.

Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL.

Cell Death Differ. 2008 May;15(5):841-8. doi: 10.1038/sj.cdd.4402309. Epub 2008 Jan 25.

15.

The RING finger domain of MDM2 is essential for MDM2-mediated TGF-beta resistance.

Kannemeier C, Liao R, Sun P.

Mol Biol Cell. 2007 Jun;18(6):2367-77. Epub 2007 Apr 11.

16.

Convergent solid-phase and solution approaches in the synthesis of the cysteine-rich Mdm2 RING finger domain.

Vasileiou Z, Barlos K, Gatos D.

J Pept Sci. 2009 Dec;15(12):824-31. doi: 10.1002/psc.1182.

PMID:
19824037
17.

Unlocking the Mdm2-p53 loop: ubiquitin is the key.

Clegg HV, Itahana K, Zhang Y.

Cell Cycle. 2008 Feb 1;7(3):287-92. Epub 2007 Nov 25. Review.

PMID:
18235222
18.

Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis.

Zheng T, Wang J, Zhao Y, Zhang C, Lin M, Wang X, Yu H, Liu L, Feng Z, Hu W.

Nat Commun. 2013;4:2996. doi: 10.1038/ncomms3996.

19.

FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53.

Ochocka AM, Kampanis P, Nicol S, Allende-Vega N, Cox M, Marcar L, Milne D, Fuller-Pace F, Meek D.

FEBS Lett. 2009 Feb 18;583(4):621-6. doi: 10.1016/j.febslet.2009.01.009. Epub 2009 Jan 21.

20.

E2F1 inhibits MDM2 expression in a p53-dependent manner.

Tian X, Chen Y, Hu W, Wu M.

Cell Signal. 2011 Jan;23(1):193-200. doi: 10.1016/j.cellsig.2010.09.003. Epub 2010 Sep 17.

PMID:
20837136

Supplemental Content

Support Center